Quantifiable Impact:
The Chaonei Inc. Performance Advantage
BOTTOM LINE: Less waiting. Lower hidden costs. Better data.
You invest heavily in generating clinical evidence AND in building scientific influence & securing market access.
Yet, these critical tracks operate in separate parallel silos in most organizations.
Strategic Blind Spots (missed trial insights)
Operational Delays (vendor complexity)
Diminished Impact (delayed influence on prescribing)
Chaonei Inc. exists to fuse these two tracks into one integrated engine
—Focused exclusively on Obstetrics & Gynecology and Neurology
One team. Two capabilities. Continuous feedback.
We are neither a standalone CRO nor a media agency. We are built as a"single operational system"with two synchronized functions working in lockstep
Deep, focused clinical development expertise in OB/GYN and Neurology.
Real-world physician-patient insights, robust KOL networks, and strategic scientific content amplification.
These two functions do not simply hand off work—they share data, insights, and milestones in real time. That's the Dual Engines model: Media makes CRO faster. CRO makes Media credible.
Physician surveys & patient journey data:
Inform better, more patient-centric protocol design.
Pre-built KOL networks:
Enable rapid site ID and a 95%+ first-pass ethics approval rate.
Patient education communities:
Serve as pre-screening channels, leading to enrollment 30–50% fasterthan industry average.
Trial data:
Generates exclusive, compelling scientific narratives, not generic health education.
Real-world evidence:
Translated into impactful peer-reviewed publications, congress presentations & KOL-led education.
Transparent compliance:
Builds prescriber and patient trust, accelerating product adoption.
BOTTOM LINE: Less waiting. Lower hidden costs. Better data.
Our CRO team delivered robust Real-World Evidence (RWE) and publication-ready data. Our Media team then amplified these findings through top-tier journals, key congresses, and national KOL livestreams.
Patient inquiries increased by 300%.65%of informed patients specifically requested the drug. First-year demand was so strong it led to stock-outs and accelerated formulary inclusion.
Evidence, amplified with credibility, directly converts to commercial momentum.
Our Media team built KOL consensus and patient education in the Obstetrics and Gynecology (OB/GYN) field from the ground up. Our CRO team then leveraged that established trust to rapidly activate 20 clinical sites
• KOL awareness doubled
• Enrollment stayed on track
• Product became a key driver of category growth
Insight work done early makes clinical execution predictable and powerful.
One team, one vision.
Work with a single, cohesive team of clinical scientists and medical strategists. No more managing two separate vendors.
Gain access to our established relationships with KOLs and professional societies in OB/GYN and Neurology.
Our integrated approach removes the biggest friction in drug development: the gap between strategic insight and flawless execution.
The competitive advantage of integration.
One team, one workflow, and seamless communication lead to significantly shorter timelines, accelerating your time-to-market.
Our bundled service model reduces the total cost of ownership compared to separate procurement from multiple vendors, streamlining your budget.
End-to-end oversight from initial insight through to final communication means fewer missteps and predictable, high-quality results.